The firm is advancing a Phase III confirmatory trial of Modeyso to potentially expand its use into newly diagnosed glioma patients.

Novo Nordisk will use Replicate's self-replicating RNA platform to develop drugs for obesity, type 2 diabetes, and other conditions.

The biotech firm launched the Phase Ib trial of Tune-401 in New Zealand and Hong Kong, making it the first pipeline candidate to enter clinical trials.

Based on preliminary Phase I data from 21 patients, the firm hopes to eventually pursue accelerated approval for MT-601.

The Phase II trial could provide registrational data on Treos' peptide immunotherapy and Junshi's PD-1 inhibitor in MSS colorectal cancer.

The pilot project is part of Project Mosaic, an effort to create better disease models of sporadic ALS and spur development of precision drugs.

The project has an €8 million grant from the EU Innovative Health Initiative and will receive additional funding from member companies.

A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

The company, founded in 2022, last year raised $52 million in a Series A funding round led by investors Eight Roads and 3E Bioventures.

NEW YORK – GSK will roll out its anti-PD-1 therapy Jemperli (dostarlimab) for certain endometrial cancer patients and its PARP inhibitor Zejula (niraparib) for ovarian cancer patients in India.

Researchers hope to test the product's ability to clear symptoms in patients with the rare genetic disorder driven by RPS19 ...